Company Performance Metrics
- Mark Voll: Chief Financial OfficerPast Role: Achronix Semiconductor, Chief Financial Officer
James M. Ahlers: Chief Financial OfficerPast Role: Intarcia Therapeutics, CFO
RenovoRx is a developing innovative solutions for targeted delivery of fluids, including diagnostic and therapeutic agents, to selected sites in the peripheral vascular system. RenovoRx received FDA clearance for the RenovoCath™ RC120 and is currently introducing this innovative technology to the clinical market.
RenovoRx has a motivated
Management Team with broad experience and an exciting vision for the future of targeted delivery. The company also has a broad Advisory Board of interventional radiologists, surgical oncologists and gastroenterologists that guide the company's clinical development strategies. RenovoRx is backed by a strong Board of Directors committed to long-term, continuous support of the company, whose members provide critical expertise in the medical and biotechnology industry and the visionary thinking to succeed.
